<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121095</url>
  </required_header>
  <id_info>
    <org_study_id>424Sm32</org_study_id>
    <nct_id>NCT00121095</nct_id>
  </id_info>
  <brief_title>Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer</brief_title>
  <official_title>Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytogen Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytogen Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and anti-tumor effects&#xD;
      of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with&#xD;
      castrate metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal objective of this trial is to evaluate the safety, feasibility, and anti-tumor&#xD;
      effects of a novel bone-targeted regimen consisting of Samarium Sm-153 lexidronam combined&#xD;
      with docetaxel and prednisone. This present study design permits evaluation of the clinical&#xD;
      activity of combining two distinct agents that have shown benefit for the treatment of&#xD;
      patients with advanced androgen-independent prostate cancer and bone metastases. It enables&#xD;
      assessment of potential synergistic interactions between a cytotoxic chemotherapy agent and a&#xD;
      bone-targeting radioisotope agent in the setting of a bone-targeted therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome is safety and tolerability of the combination treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response will be assessed when possible using RECIST criteria.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Samarium Sm-153 lexidronam + Docetaxel</intervention_name>
    <description>1 mCi/kg Sm153 + 75 mg/m2 docetaxel</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histological evidence of adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Have progressive castrate metastatic disease.&#xD;
&#xD;
          -  Castrate levels of testosterone (&lt;50 ng/ml). Treatment to maintain castrate levels of&#xD;
             testosterone must be continued.&#xD;
&#xD;
          -  Must have evidence of at least 3 bone metastases on bone scan.&#xD;
&#xD;
          -  Patients for whom initial hormone treatment (exclusive of neoadjuvant hormone therapy)&#xD;
             was a combined androgen blockade approach, must show progression of disease following&#xD;
             withdrawal of the anti-androgen prior to enrollment.&#xD;
&#xD;
          -  Patients undergoing prior bisphosphonate treatments are eligible.&#xD;
&#xD;
          -  Patients who have received one prior treatment with 153Sm lexidronam or 89Sr are&#xD;
             eligible provided it is at least 12 weeks from treatment with 153Sm lexidronam or 24&#xD;
             weeks from treatment with 89Sr.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks (based on co-morbidity).&#xD;
&#xD;
          -  KPS&gt;60.&#xD;
&#xD;
          -  Lab requirements:&#xD;
&#xD;
               -  White Blood Count (WBC) ≥ 3,000/mm3;&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1,500/ mm3;&#xD;
&#xD;
               -  Platelet (PLT) ≥ 100,000/mm3;&#xD;
&#xD;
               -  Hemoglobin (HGB) ≥ 10 mg/dl;&#xD;
&#xD;
               -  Bilirubin ≤ 2.0 mg/dl;&#xD;
&#xD;
               -  ALT/AST≤ 3 times the upper limit of normal;&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 mg/dl.&#xD;
&#xD;
          -  Patients must sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with small cell carcinoma.&#xD;
&#xD;
          -  Patients with predominant visceral metastases (&gt;3 lung or liver lesions) or&#xD;
             symptomatic lymphadenopathy (scrotal or pedal edema).&#xD;
&#xD;
          -  Patients who have received more than one course of external beam radiation therapy&#xD;
             directed at bone lesions.&#xD;
&#xD;
          -  Clinically significant cardiac disease (New York Heart Association Class III/IV).&#xD;
&#xD;
          -  History of other malignancies (other than non-melanoma skin cancer), unless in&#xD;
             complete remission or off therapy for that disease for at least five years.&#xD;
&#xD;
          -  Have or are participating in a research study protocol or clinical trial protocol&#xD;
             within 30 days of the date of the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Morris, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Gramkowski</last_name>
    <phone>800-833-3533</phone>
    <phone_ext>8219</phone_ext>
    <email>cgramkowski@cytogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Giles</last_name>
    <phone>800-833-3533</phone>
    <phone_ext>8112</phone_ext>
    <email>mgiles@cytogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Morris</last_name>
      <phone>646-422-4469</phone>
    </contact>
    <investigator>
      <last_name>Michael J Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>July 13, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <responsible_party>
    <name_title>Michael Manyak, MD</name_title>
    <organization>Cytogen Corporation</organization>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Samarium Sm-153 lexidronam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

